Shin Nippon Biomedical reports lower FY2026 net profit

4 articles · Updated · MarketWatch · May 11

For the year ended 31 March, net profit fell to Y4.57bn from Y4.92bn, while revenue edged up to Y32.52bn from Y32.41bn.
Operating profit declined to Y2.65bn from Y2.99bn, pretax profit to Y5.83bn from Y6.45bn, and earnings per share to Y109.69 from Y118.29.
The Japanese company said the results were prepared under Japanese accounting standards, showing slightly higher sales but weaker profitability across key earnings measures.

Is SNBL's new blood-collection venture a costly gamble or a key to future growth in Japan's healthcare?

With revenue rising, why did SNBL's profits fall during a boom in the global CRO market?

As AI transforms drug research, can SNBL's specialized animal models maintain its competitive edge against tech-driven rivals?